Pharma Stocks

Aurobindo Pharma nears all-time high, up 30% in 4 months; more upside left?

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Dr Reddys gains over 4%; hits 52-week high on near 3X jump in volume

Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Aurobindo Pharma stock jumps 2% after US FTC approves Lannett acquisition

Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.

New launches, India business growth key triggers for Zydus Lifesciences

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Pharma, healthcare funds are in recovery mode. Should you enter them now?

Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Cipla gains US FDA nod for Ventolin; analysts see $100 mn sales potential

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Sun Pharma stock falls 5% in strong market: What's worrying investors?

Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Blue Jet Healthcare tanks 19% in 2 days; nears issue price; here's why

The company said decrease in revenue from operations during Q3FY26 is due to lower sales of PI and Artificial Sweeteners.